Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening
Clinical Gastroenterology and Hepatology · 2023
DOI: 10.1016/j.cgh.2023.07.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Arthur Kooyker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Gastroenterology and Hepatology, Leiden Uni…. Hauptthemen laut MEDLINE: Early Detection of Cancer, Colorectal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujifilm Corporation, Rijksinstituut voor Volksgezondheid en Milieu, Medtronic.
Abstract (Originalsprache)
BACKGROUND & AIMS: For colorectal cancer (CRC) screening to be effective, it is important that screen-detected cancers are found at an early stage. Studies on stage distribution of screen-detected CRC at repeat screening of large population-based fecal immunochemical test (FIT)-based screening programs and the impact of FIT cut-off values on staging currently are lacking. METHODS: We obtained data for FIT-positive participants (FIT cut-off, 47 μg hemoglobin/g feces) at their first or second (ie, repeat) screening from the Dutch National Screening Database from 2014 to 2018. Tumor characteristics were acquired through linkage with The Netherlands Cancer Registry. We compared stage at diagnosis (I-II vs III-IV) of CRCs detected at a first or second screening. In addition, we analyzed the hypothetical yield and stage distribution of CRC for different FIT cut-off values up to 250 μg hemoglobin/g feces. RESULTS: At the first and second screenings, respectively, 15,755 and 3304 CRCs were detected. CRCs detected at the first or second screening were equally likely to be stages I to II (66.5% vs 67.7%; relative risk, 1.02; 95% CI, 1.00-1.05). A hypothetical increase of the FIT cut-off value from 47 μg to 250 μg resulted in a reduction of detected CRCs by 88.3% and 79.0% at the first or second screening, respectively. Even then, the majority of detected CRCs (63%-64%) still would be diagnosed at stages I to II. CONCLUSIONS: FIT-based screening is effective in downstaging CRC, and also at repeat screening. Increasingly, the FIT cut-off level has a limited impact on the stage distribution of detected CRCs, although it greatly affects CRC detection and thus is important to keep low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: a…
- Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, The Netherlands.
Förderung
- Fujifilm Corporation
- Rijksinstituut voor Volksgezondheid en Milieu
- Medtronic
Zitieren
APA
Kooyker, A., de Jonge, L., Toes-Zoutendijk, E., Spaander, M., van Vuuren, H., Kuipers, E., van Kemenade, F., Ramakers, C., Dekker, E., Nagtegaal, I., van Leerdam, M., & Lansdorp-Vogelaar, I. (2023). Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.07.028
Vancouver
Kooyker A, de Jonge L, Toes-Zoutendijk E, Spaander M, van Vuuren H, Kuipers E, et al. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.07.028
BibTeX
@article{Kooyker2023,
author = {Kooyker, Arthur and de Jonge, Lucie and Toes-Zoutendijk, Esther and Spaander, Manon and van Vuuren, Hanneke and Kuipers, Ernst and van Kemenade, Folkert and Ramakers, Chris and Dekker, Evelien and Nagtegaal, Iris and van Leerdam, Monique and Lansdorp-Vogelaar, Iris},
title = {Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
doi = {10.1016/j.cgh.2023.07.028}
}
EUVIMED